Q32 Bio Inc
USUSDQ32 Bio Inc (US:QTTB) — Biotechnology: Pharmaceutical Preparations. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 2. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.
À propos de l'entreprise
- Site Web
- q32bio.com
- Secteur
- Health Care · Biotechnology: Pharmaceutical Preparations
- Siège Social
- WALTHAM, United States
- PDG
- Jodie Pope Morrison
- Employés
- 22
- Actions en Circulation
- 29.77 M au 2026-08-03
- Flottant
- 14.64 M
- Capitalisation Boursière
- 248.28 M USD
- Initiés
- 2.1%
- Investisseurs Institutionnels
- 80.73%
- Secteur d'Activité (SIC)
- Pharmaceutical Preparations
- FCF
- −33.5 M USD
- Dette
- 0 USDtrésorerie nette
- Résultats et FCF — pour les 12 mois à 30.06.2026 (dernier rapport de l'entreprise).
Description
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.
Principaux Actionnaires
| Détenteur | Participation | Actions | Date du Rapport |
|---|---|---|---|
| Orbimed Advisors LLC. | 13.87% | 4.13 M | 2026-06-30 |
| Boxer Capital Management… | 10.58% | 3.15 M | 2026-06-30 |
| Atlas Venture Life Scien… | 9.13% | 2.72 M | 2026-06-30 |
| BVF Inc. | 7.89% | 2.35 M | 2026-06-30 |
| RA Capital Management, L… | 7.84% | 2.33 M | 2026-06-30 |
| Point72 Asset Management… | 3.94% | 1.17 M | 2026-06-30 |
| Opaleye Management Inc. | 3.13% | 931 000 | 2026-06-30 |
| Logos Global Management… | 2.69% | 800 000 | 2026-06-30 |
| Summittx Capital, L.P. | 2.46% | 733 774 | 2026-06-30 |
| Vanguard Capital Managem… | 1.74% | 518 803 | 2026-06-30 |
| American Century ETF Tru… | 1.74% | 518 252 | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 1.31% | 389 115 | 2026-06-30 |
| MORRISON JODIE POPE (Chi… | ≈1.15% | 343 259 | 2026-08-25 |
| VIOLETTE SHELIA M (Offic… | ≈0.55% | 164 048 | 2026-08-25 |
| KALOWSKI LEE (President) | ≈0.47% | 138 471 | 2026-08-25 |
| VANGUARD INDEX FUNDS-Van… | 0.4% | 119 269 | 2026-06-30 |
| MANKE ISAAC (Director) | ≈0.18% | 53 521 | 2026-06-30 |
| Fidelity Concord Street… | 0.17% | 51 015 | 2026-07-31 |
| First TRT Exch-Trd Fd.-F… | 0.15% | 45 411 | 2026-08-31 |
| CAMPAGNA JASON (Officer) | ≈0.13% | 37 500 | 2025-02-24 |
| Bridgeway Funds, Inc.-Ul… | 0.12% | 34 613 | 2026-06-30 |
| iShares Trust-iShares Mi… | 0.1% | 29 271 | 2026-08-31 |
| American Century ETF Tru… | 0.08% | 22 622 | 2026-08-31 |
| Fidelity Concord Street… | 0.07% | 19 792 | 2026-07-31 |
| American Century ETF Tru… | 0.06% | 17 858 | 2026-08-31 |
| ORBIMED ADVISORS, L.L.C.… | — | — | 2026-05-28 |
| XU DIYONG (Director and… | — | — | 2026-05-28 |
